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Abstract 
Background: To examine the association between the type of preceding oral anticoagulant use 
(warfarin or direct oral anticoagulants [DOACs]) and in-hospital mortality among patients admitted 
with gastrointestinal bleeding. 
Methods and Results: In this observational cohort study, all patients admitted with a first-time 
gastrointestinal bleeding from January 2011 to March 2017 while receiving any oral anticoagulant 
therapy prior to admission were identified using data from Danish nationwide registries. The risk of 
in-hospital mortality according to type of oral anticoagulation therapy was examined by 
multivariable logistic regression models. Among 5,774 patients admitted with gastrointestinal 
bleeding (median age, 78 years [25
th
-75
th
 percentile, 71-85 years]; 56.8% men), 2,038 (35.3%) were 
receiving DOACs and 3,736 (64.7%) were receiving warfarin prior to admission. The unadjusted 
in-hospital mortality rates were 7.5% for DOAC (7.2% for dabigatran, 6.4% for rivaroxaban, and 
10.1% for apixaban) and 6.5% for warfarin. After adjustment for baseline demographic and clinical 
characteristics, there was no statistically significant difference in in-hospital mortality between prior 
use of any DOAC and warfarin (unadjusted odds ratio [OR] 1.18 [95% confidence interval 
[CI],0.95-1.45], adjusted OR 0.97 [95%CI,0.77-1.24]). Similar results were found for each 
individual DOAC as compared with warfarin (dabigatran, unadjusted OR 1.12 [95%CI,0.84-1.49], 
adjusted OR 0.96 [95%CI,0.71-1.30]); rivaroxaban, unadjusted OR 0.98 [95%CI,0.71-1.37], 
adjusted OR 0.84 [95%CI,0.59-1.21]; and apixaban, unadjusted OR 1.62 [95%CI,0.84-1.49], 
adjusted OR 1.22 [95%CI, .83-1.79]). 
Conclusions: Among patients admitted with gastrointestinal bleeding, there was no statistically 
significant difference in in-hospital mortality between prior use of DOAC and warfarin. 
 
Key words: Epidemiology; oral anticoagulation therapy; gastrointestinal bleeding.  
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Introduction 
During the last decade, direct oral anticoagulants (DOACs) have emerged as alternatives to vitamin 
K antagonists (VKA) for the prevention of stroke and systemic thromboembolism in high-risk 
patients with non-valvular atrial fibrillation (NVAF) and have been rapidly adopted into clinical 
practice.
1-5
 Compared with warfarin, DOACs reduce the risk of stroke and systemic 
thromboembolism and have a favorable safety profile with respect to the risk of major and 
intracerebral hemorrhage.
6, 7
 Despite their safety, DOACs increase the risk of bleeding 
complications, especially gastrointestinal (GI) bleeding.
6, 7
 However, unlike warfarin, no antidote or 
reversal agent was available for any of the DOACs until the approval of Idarucizumab in October 
2015 and Andexanet Alpha in May 2018. The lack of a reversal agent raises concern whether 
DOAC-related bleeding more frequently results in death compared with bleeding events associated 
with the use of warfarin, a medication whose effects can be rapidly reversed by vitamin K, plasma, 
and prothrombin complex concentrates. A recent study showed that prior use of DOACs was 
associated with lower risk of severe stroke and in-hospital mortality among patients with 
intracerebral hemorrhage compared with prior use of warfarin.
8
 However, data regarding DOAC-
related GI bleeding, which is the most common serious complication of oral anticoagulation, are 
limited. Whether the type of OAC treatment prior to admission may lead to differential severity of 
GI bleeding and subsequent adverse outcomes has been sparsely studied.
9-13
 Thus, a better 
understanding of the outcomes among patients experiencing a GI bleeding according to the type of 
preceding anticoagulant use is necessary and warrants further investigation. This gap in knowledge 
prompted us to conduct a Danish nationwide retrospective cohort study to examine in-hospital 
mortality among patients admitted with GI bleeding according to the type of preceding 
anticoagulant use in an era where specific reversal agents for DOACs were largely unavailable. 
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Methods 
Data sources 
All residents in Denmark are assigned a unique and permanent civil registration number allowing 
accurate linkage of nationwide administrative registries at an individual level over time. For this 
study, data from the following nationwide administrative registries were collected: The Danish 
National Patient Registry holds information on all hospital admissions and outpatient contacts 
according to the International Classification of Diseases (ICD-8 until 1994 and ICD-10 from 1994) 
and all surgical procedures according to the NOMESCO Classification of Surgical Procedures 
(NCSP);
14
 the Danish Registry of Medicinal Product Statistics (the Danish National Prescription 
Registry) contains detailed information on dispensing date, strength, and quantity on all claimed 
drug prescriptions in Denmark;
15
 and the Danish Civil Registration System holds information on 
birth date, sex, and vital status (i.e. whether a person is alive and resident in Denmark, disappeared 
[persons whose residence is unknown to Danish authorities], emigrated, or dead, along with the date 
of these events).
16
 
 
Study population 
All Danish residents with a primary discharge diagnosis of GI bleeding between January 1, 2011 
and June 30, 2017 were identified. Patients were included in the study if they had no history of GI 
bleeding (i.e. those who did not have a primary or secondary in-hospital or outpatient diagnosis of 
GI bleeding any time prior to admission until 1994) and had a prescription for OAC medication in 
the 3 months prior to admission. The study population was stratified into two groups, the warfarin 
and DOAC group (i.e. dabigatran, rivaroxaban, and apixaban), based on the most recent 
prescription for OAC medication prior to GI bleeding. Less than 5 patients admitted with GI 
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bleeding were in treatment with edoxaban. Therefore, these patients were excluded from the 
analyses. 
 
Covariates 
Comorbidity was obtained using in-hospital and outpatient diagnoses any time prior to admission 
for GI bleeding (eTable 1 for ICD-8 and ICD-10 codes) with the following exceptions: cancer was 
defined using hospital discharge diagnoses in the 3 years prior to admission; diabetes and 
hypertension were identified using claimed drug prescriptions, as done previously;
17, 18
 and alcohol 
abuse was defined from related prescription fills and ICD-10 diagnosis codes. Concomitant 
pharmacotherapy was defined as filled prescriptions within 180 days prior to admission (eTable 2 
for Anatomical Therapeutic Chemical Classification System codes). In-hospital endoscopic 
procedures were defined as procedures performed during admission (eTable 3 for NCSP codes). 
The duration of OAC therapy prior to admission for GI bleeding was estimated using claimed 
consecutive prescriptions, taking dosage and packing size into account, as done previously.
19, 20
 The 
estimated risk of stroke (CHA2DS2-VASc-score) and bleeding (a modified HAS-BLED-score 
[international normalized ratio left out due to the lack of data]) was calculated as described 
previously.
21, 22
 
 
Outcomes 
The primary outcome was in-hospital mortality, defined as the date of death – retrieved from the 
Danish Civil Registration System – during admission for GI bleeding. 
 
Statistics 
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Descriptive data were reported as frequencies and percentages or medians with 25
th
-75
th
 percentile 
as appropriate. Differences in baseline characteristics according to type of OAC were examined by 
Chi-square test or Fisher’s exact test for categorical variables and Kruskal-Wallis test for 
continuous variables. Multivariable logistic regression models were used to estimate odds ratios 
(OR) with 95% confidence intervals (CI), adjusted for age, sex, comorbidity, concomitant 
pharmacotherapy, duration of OAC therapy, and year of admission. The warfarin group served as 
the reference group in all models. Prespecified subgroup analyses of the primary outcome were 
performed for the following variables: Age, sex, source of bleeding, atrial fibrillation, venous 
thromboembolism, cancer, and in-hospital endoscopic procedure. All statistical analyses were 
performed with SAS statistical software (SAS 9.4, SAS Institute, Cary, North Carolina, USA). A 
two-sided p-value <0.05 was considered statistically significant. The authors are solely 
responsible for the design and conduct of this study, all study analyses, the drafting and 
editing of the paper and its final contents. 
 
Ethics 
This study was approved by the Danish Data Protection Agency (No. 2007-58-0015; internal 
reference: GEH-2014-013, I-Suite no. 02731). In Denmark, ethical approval is not required for 
register-based studies in which individuals cannot be identified. 
 
Sources of funding 
No extramural funding was used to support this work. 
 
Results 
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From January 1, 2011 to June 30, 2017, 40,812 patients admitted with GI bleeding with no history 
of GI bleeding any time prior to admission were identified. Of these, 5,774 (14.1%) patients 
received OAC therapy prior to admission and were included in the study (Figure 1). In total, 3,736 
(64.7%) patients received warfarin prior to admission, while 892 (15.4%), 708 (12.3%), and 438 
(7.6%) patients received dabigatran, rivaroxaban, and apixaban, respectively. The median age of the 
study population was 78 years (25
th
-75
th
 percentile 71-85) and 56.8% were men. Baseline 
characteristics of the study population according to OAC therapy are summarized in Table 1. 
Compared with patients receiving warfarin, patients receiving DOACs were characterized by a 
higher proportion of females, older age, greater prevalence of atrial fibrillation, and lower 
proportion of congestive heart failure, ischemic heart disease, peripheral vascular disease, chronic 
kidney disease, diabetes, and venous thromboembolism. Further, a lower proportion of patients 
received antiplatelet therapy prior to admission in the DOAC group compared with the warfarin 
group. 
 
Source of bleeding 
The distribution of the source of bleeding is shown in Table 2. Compared with patients with prior 
use of warfarin, a significantly lower proportion of patients with prior use of DOAC were admitted 
with upper GI bleeding. In patients with prior use of DOAC, a higher proportion of patients 
receiving apixaban were admitted with upper GI bleeding compared with dabigatran and 
rivaroxaban. 
 
Endoscopic procedures 
During admission, 1,227 (60.2%) and 2,533 (67.8%) patients with prior use of DOAC and warfarin, 
respectively, underwent at least one endoscopic procedure. The distribution of endoscopic 
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procedures performed during admission is shown in Table 2. Compared with patients with prior use 
of warfarin, a significantly lower proportion of patients with prior use of DOAC underwent 
esophago-/gastro-/duodenoscopy, whereas a similar proportion of patients in both groups underwent 
sigmoido-/colonoscopy. In patients with prior use of DOAC, a numerically lower proportion of 
patients receiving apixaban underwent an endoscopic procedure compared with dabigatran and 
rivaroxaban. A numerically higher proportion of patients with prior use of rivaroxaban underwent 
esophago-/gastro-/duodenoscopy, while a significantly higher proportion of patients receiving 
dabigatran underwent sigmoido-/colonoscopy. 
 
In-hospital mortality 
The unadjusted in-hospital mortality rates for patients with prior use of DOACs and warfarin were 
7.5% (153/2,038) and 6.5% (241/3,736), respectively. In patients with prior use of dabigatran, 
rivaroxaban, and apixaban, the unadjusted in-hospital mortality rates were 7.2% (64/892), 6.4% 
(45/708), and 10.1% (44/438), respectively. The results from the multivariable adjusted logistic 
regression models are illustrated in Figure 2. Prior use of any DOAC was not associated with a 
statistically significant difference in in-hospital mortality compared with prior use of warfarin 
(unadjusted odds ratio [OR] 1.18 [95% confidence interval [CI], 0.95-1.45], adjusted OR 0.97 [95% 
CI, 0.77-1.24]). Likewise, compared with prior use of warfarin, prior use of dabigatran (unadjusted 
OR 1.12 [95% CI, 0.84-1.49], adjusted OR 0.96 [95% CI, 0.71-1.30]), rivaroxaban (unadjusted OR 
0.98 [95% CI, 0.71-1.37], adjusted OR 0.84 [95% CI, 0.59-1.21]), and apixaban (unadjusted OR 
1.62 [95% CI, 0.84-1.49], adjusted OR 1.22 [95% CI, 0.83-1.79]) were not associated with a 
statistically significant difference in in-hospital mortality. 
The results of the prespecified subgroup analyses are displayed in Figure 3. There was 
no statistically significant interaction between the treatment group and each subgroup. As in the 
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main analysis, the subgroup analyses overall demonstrated that prior use of DOACs was not 
associated with a statistically significant difference in in-hospital mortality compared with prior use 
of warfarin. 
 
Sensitivity analysis 
A number of sensitivity analyses were performed to test the robustness of these findings. 
1) To examine the association between preceding oral anticoagulant use and in-hospital mortality in 
an era, where reversal agents for DOACs were available, the inclusion period was restricted to 
December 1, 2015 and June 30, 2017. As in the main analysis, prior use of DOACs was not 
associated with a statistically significant difference in in-hospital mortality compared with prior use 
of warfarin (unadjusted OR 1.03 [95% CI, 0.70-1.50], adjusted OR 0.84 [95% CI, 0.57-1.26]). 
2) Patients were included only if they had a prescription for OAC medication in the 30 days prior to 
admission. This analysis yielded similar findings as in the main analysis (unadjusted OR 1.20 [95% 
CI, 0.92-1.58], adjusted OR 0.88 [95% CI, 0.66-1.18]). 
3) To account for differences in the duration of hospital stay, we compared the risk of 30-day 
mortality among patients receiving DOACs and warfarin, respectively. The unadjusted 30-day 
mortality rates for patients with prior use of DOACs and warfarin were 11.3% (231/2,038) and 
8.6% (322/3,736), respectively. Prior use of any DOAC was not associated with a statistically 
significant difference in 30-day mortality compared with prior use of warfarin (unadjusted OR 1.36 
[95% CI, 1.13-1.62], adjusted OR 1.04 [95% CI, 0.85-1.28]). 
4) Propensity score stratification analysis was performed to account for differences in baseline 
characteristics. Propensity scores were calculated using logistic regression with OAC treatment as 
the dependent outcome and were generated from the covariates adjusted for in the primary logistic 
regression model. ORs were calculated using logistic regression stratified in five groups according 
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to the propensity to DOAC treatment. Stratification on propensity scores ensured comparison only 
within strata of propensity scores. The C-index of the propensity model was 0.67. As in the main 
analysis, prior use of DOACs was not associated with a statistically significant difference in in-
hospital mortality compared with prior use of warfarin (OR 0.93 [95% CI, 0.80-1.07]). 
 
Discussion 
In this nationwide cohort study, we examined the association between type of preceding 
anticoagulant use and in-hospital mortality among patients admitted with GI bleeding. The main 
finding of this study is that there was no significant difference in the risk of in-hospital mortality 
between prior use of DOACs and warfarin among patients admitted with GI bleeding. 
Although the efficacy of DOACs for the prevention of stroke and systemic 
thromboembolism is well-established, a major safety concern in clinical practice has been the lack 
of specific reversal agents or antidotes. Only recently, idarucizumab and andexanet alfa were 
approved for emergent reversal of dabigatran and factor Xa inhibitors, respectively. Several studies 
have compared case-fatality among patients who experience any bleeding while receiving DOAC 
and those who experience any bleeding while receiving warfarin, for which an established reversal 
strategy is available. Xu et al. found that in patients with oral anticoagulant-related bleeding (460 
receiving DOACs and 1,542 receiving warfarin), in-hospital mortality was lower among DOAC-
related bleeding events compared with warfarin-related bleeding events (9.8% vs 15.2%; adjusted 
relative risk, 0.66, 95% CI, 0.49-0.89) despite high rates of warfarin reversal with vitamin K and 
prothrombin complex concentrates in the warfarin group.
23
 In a meta-analysis of 20 randomized 
trials including 1,976 major DOAC-related bleeding events and 2,080 major warfarin-related 
bleeding events, prior use of DOAC was associated with a lower risk of a fatal bleeding compared 
with prior use warfarin (OR, 0.65, 95% CI, 0.52-0.81).
24
 Likewise, a meta-analysis of 12 
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randomized trials reported that in patients with major bleeding, prior use of DOACs was associated 
with lower case-fatality compared with prior use of warfarin.
25
 A recent large study specifically 
addressed the association between preceding oral anticoagulant use and in-hospital mortality among 
patients with intracerebral hemorrhage and found that prior use of NOACs, compared with prior use 
of warfarin, was associated with lower risk of in-hospital mortality.
8
 Thus, mounting evidence 
suggest that among patients admitted with bleeding or specifically intracerebral hemorrhage, prior 
use of DOACs is associated with at least similar, or even better, outcomes than warfarin use. 
However, studies specifically addressing in-hospital mortality among patients experiencing oral 
anticoagulant-related GI bleeding are scarce and limited by a small number of patients with DOAC-
related bleeding. In a recent study including 143 patients with DOAC-related GI bleeding and 185 
patients with VKA-related GI bleeding, in-hospital mortality was lower in patients with prior use of 
DOACs compared with prior use of VKAs (1.6% and 5.6%, respectively).
9
 A second study did not 
find a significant difference in the 30-day mortality risk among groups in a cohort of 88 and 151 
patients with DOAC- and warfarin-related GI bleeding, respectively (11% vs 7%; hazard ratio 1.76, 
95% CI, 0.65-4.76).
11
  
To our knowledge, our study is the first to examine in-hospital mortality in a large 
nationwide, unselected cohort of patients specifically admitted with GI bleeding according to the 
type of preceding anticoagulant use. In line with previous studies, we found that prior use of 
DOACs was not associated with a significant difference in in-hospital mortality among patients 
admitted with GI bleeding as compared with prior use of warfarin. This finding is reassuring in light 
of the absence of specific reversal agents for DOACs during the study period and the availability of 
a well-established reversal strategy for warfarin-related bleedings with vitamin K, plasma, and 
prothrombin complex concentrates. Our findings may be partly explained by be the short half-life of 
DOACs and possibly that DOAC patients may have had less severe bleedings, efficacy of 
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endoscopic or other interventional therapy, and the fact that anticoagulant-related GI bleeding is a 
marker of generalized illness. In any case, our data support the safety of DOACs in routine clinical 
practice, even in an era where specific reversal agents for DOACs were largely unavailable. 
In an additional analysis, we compared each of the DOACs with warfarin with regards 
to the risk of in-hospital mortality. As in the main analysis, there was no significant difference in in-
hospital mortality between each of the DOACs and warfarin. Despite the fact that both randomized 
trials and observational data have raised concern on the risk of GI bleeding associated with DOACs, 
especially dabigatran, 
6, 7
 these findings suggest that DOAC-related GI bleeding regardless of type 
of DOAC is not associated with worse outcomes than warfarin-related GI bleeding. These findings, 
however, should be interpreted with caution as our study was not powered to detect a significant 
difference in in-hospital mortality between each of the DOACs and warfarin. 
An interesting observation in this study was that a higher proportion of patients 
receiving warfarin underwent in-hospital endoscopic procedures compared with those receiving 
DOACs. Although speculative, a possible explanation may be that a lower proportion of patients 
receiving DOACs had an upper gastrointestinal bleeding and that DOAC patients may have had less 
severe bleedings and thus were less likely to receive endoscopic treatment than those receiving 
warfarin. This, which is also supported by the shorter hospital stay in the DOAC group. 
Importantly, there was no significant difference in in-hospital mortality among patients receiving 
DOACs and warfarin when restricting the study population to those who underwent in-hospital 
endoscopic procedures. 
 
Strengths and limitations 
The main strength of this study is the completeness of data in a large nationwide unselected cohort 
of patients admitted with GI bleeding. The Danish healthcare system, funded by taxes, provides 
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equal access to healthcare services for all residents regardless of socioeconomic or insurance status. 
Since 1871, it has been mandatory by law to complete a death certificate in any case of death 
occurring in Denmark. In Denmark, OACs can be purchased only through prescription. Due to 
partial reimbursement of drug expenses by the Danish healthcare system, pharmacies are required to 
register all redeemed prescriptions ensuring complete and accurate registration. The findings of this 
study should be viewed in the context of a number of limitations. The observational nature of this 
study precludes the assessment of cause-effect relationships. Instead, we examined the association 
between in-hospital mortality and prior use of DOACs or warfarin in OAC-related GI bleeding. The 
possibility of residual confounding cannot be excluded despite adjustment for potential confounders 
in the logistic regression models. Data on important clinical variables such as hemoglobin levels, 
creatinine levels, international normalized ratios, blood transfusions, subsequent thrombotic events, 
and intensive care unit admissions were not available. Although patients with warfarin-related GI 
bleeding presumably had the benefit of the availability of an established reversal strategy, data on 
actual use of reversal strategies, including the use of vitamin K, plasma, prothrombin complex 
concentrates, and idarucizumab were not available. However, only 20% of patients with dabigatran-
related GI bleeding were admitted after the approval of idarucizumab in Denmark (December 
2015). Finally, we did not have information on the specific type and severity of bleeding besides the 
location and endoscopic interventions. 
 
Conclusions 
In a large nationwide, unselected cohort of patients admitted with GI bleeding, prior use of a DOAC 
was not associated with a significant difference in in-hospital mortality compared with prior use of 
warfarin, even in an era where specific reversal agents for DOACs were largely unavailable. These 
findings further underline the safety of DOACs in routine care.  
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Figure legends 
Figure 1. Flow chart of the study population selection process 
 
Figure 2. Adjusted odds ratios of in-hospital mortality in patients admitted with GI bleeding 
according to prior anticoagulant therapy 
The warfarin group served as the reference group in all models 
*Adjusted for age, sex, arterial thromboembolism (ischemic stroke, transient ischemic attack, or peripheral thromboembolism), venous 
thromboembolism, a history of ischemic heart disease, atrial fibrillation, peripheral vascular disease, congestive heart failure, hypertension, 
diabetes, alcohol abuse, chronic kidney disease, chronic obstructive pulmonary disease, liver disease, malignancy, peptic ulcer, use of NSAID and 
antiplatelet therapy, duration of OAC therapy, and year of admission 
 
Figure 3. Adjusted odds ratios of in-hospital mortality in patients admitted with GI bleeding 
for prior DOAC versus warfarin use within subgroups 
The warfarin group served as the reference group in all models 
*Adjusted for age, sex, arterial thromboembolism (ischemic stroke, transient ischemic attack, or peripheral thromboembolism), venous 
thromboembolism, a history of ischemic heart disease, atrial fibrillation, peripheral vascular disease, congestive heart failure, hypertension, 
diabetes, alcohol abuse, chronic kidney disease, chronic obstructive pulmonary disease, liver disease, malignancy, peptic ulcer, use of NSAID and 
antiplatelet therapy, duration of OAC therapy, and year of admission. The Cox model for each subgroup analysis was not adjusted for the variable 
that was used to define the specific subgroup. 
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Table 1. Baseline characteristics of the study population 
 Full study population Study population with prior use of DOAC 
Characteristics 
DOAC 
N=2,038 
Warfarin 
N=3,736 
P-value 
Dabigatran 
N=892 
Rivaroxaban 
N=708 
Apixaban 
N=438 
P-value 
Demographics        
     Age, median (25
th
-75
th
 percentile) 80 (73-86) 78 (70-84) <0.001 80 (74-86) 79 (72-86) 81 (73-88) 0.007 
     Male, N (%) 997 (48.9) 2,285 (61.2) <0.001 414 (46.4) 369 (52.1) 214 (48.9) 0.08 
Comorbidities, N (%)        
     Ischemic heart disease 737 (36.2) 1,556 (41.7) <0.001 331 (37.1) 250 (35.3) 156 (35.6) 0.73 
     Atrial fibrillation 1,545 (75.8) 2,701 (72.3) 0.004 724 (81.2) 468 (66.1) 353 (80.6) <0.001 
     Heart failure 594 (29.2) 1,232 (33.0) 0.003 274 (30.7) 194 (27.4) 126 (28.8) 0.34 
     Arterial thromboembolism
a
 529 (26.0) 928 (24.8) 0.35 218 (24.4) 167 (23.6) 144 (32.9) <0.001 
     Peripheral vascular disease 185 (9.1) 420 (11.2) 0.01 87 (9.8) 63 (8.9) 35 (8.0) 0.56 
     Hypertension 1,452 (71.3) 2,703 (73.4) 0.37 670 (75.1) 480 (67.8) 302 (69.0) 0.003 
     Diabetes 324 (15.9) 700 (18.7) 0.007 150 (16.8) 102 (14.4) 72 (16.4) 0.40 
     Venous thromboembolism 311 (15.3) 766 (20.5) <0.001 63 (7.1) 185 (26.1) 63 (14.4) <0.001 
     Malignancy 301 (14.8) 529 (14.2) 0.53 127 (14.2) 111 (15.7) 63 (14.4) 0.70 
     Chronic renal disease 113 (5.5) 365 (9.8) <0.001 29 (3.3) 51 (7.2) 33 (7.5) <0.001 
     Chronic obstructive pulmonary disease 406 (19.9) 696 (18.6) 0.23 176 (19.7) 145 (20.5) 85 (19.4) 0.89 
     Peptic ulcer 214 (10.5) 458 (12.3) 0.05 85 (9.5) 81 (11.4) 48 (11.0) 0.44 
     Liver disease 71 (3.5) 135 (3.6) 0.80 21 (2.4) 30 (4.2) 20 (4.6) 0.05 
     Alcohol abuse 147 (7.2) 254 (6.8) 0.55 52 (5.8) 59 (8.3) 36 (8.2) 0.10 
Risk scores, mean (standard deviation)        
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     CHA2DS2-VASc 4.2 (1.7) 4.1 (1.7) 0.02 4.4 (1.6) 4.0 (1.7) 4.4 (1.7) <0.001 
     HAS-BLED 2.6 (1.0) 2.7 (1.1) <0.001 2.6 (1.0) 2.5 (1.0) 2.6 (1.1) 0.33 
Concomitant medical treatment, N (%)        
     Antiplatelets   <0.001    0.009 
          Single 344 (16.9) 1,030 (27.6)  167 (18.7) 127 (17.9) 50 (11.4)  
          Dual 54 (2.7) 130 (3.5)  19 (2.1) 20 (2.8) 15 (3.4)  
     Nonsteroidal anti-inflammatory drugs 343 (16.8) 582 (15.6) 0.22 162 (18.2) 109 (15.4) 72 (16.4) 0.33 
Duration of oral anticoagulant treatment, days 
(median [25th-75th percentile]) 
157 (34-484) 354 (93-968) <0.001 241 (46-607) 108 (28-358) 139 (32-400) <0.001 
aIschemic stroke, transient ischemic attack, or peripheral thromboembolism 
CHA2DS2-VASc: Congestive heart failure, hypertension, age ≥75 years (2 points), diabetes, history of stroke/transient ischemic attack/systemic thromboembolism (2 points), vascular disease, age 65–74 years, and female sex. 
HAS-BLED: Hypertension, abnormal renal/liver function, history of stroke, history of bleeding, labile International Normalized Ratio (left out due to missing data), age > 65 years, and drug consumption with antiplatelet 
agents, non-steroidal anti-inflammatory drugs, or alcohol abuse.  
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Table 2. Length of hospital stay, sSource of GI bleeding and in-hospital endoscopic procedures 
 Full study population Study population with prior use of DOAC 
 
DOAC 
N=2,038 
Warfarin 
N=3,736 
P-value 
Dabigatran 
N=892 
Rivaroxaban 
N=708 
Apixaban 
N=438 
P-value 
Hospital stay (days), median (25
th
-75
th
 percentile) 3 (1-6) 4 (2-7) 0.003 3 (1-6) 3 (1-6) 4 (1-6) 0.65 
Source of GI bleeding   <0.001    <0.001 
     Upper 786 (38.6) 1,881 (50.4)  290 (32.5) 294 (41.5) 202 (46.1)  
     Lower 849 (41.7) 1,201 (32.2)  428 (45.0) 261 (36.9) 160 (36.5)  
     Unspecified 403 (19.8) 654 (17.5)  174 (19.5) 153 (21.6) 76 (17.4)  
Endoscopy        
     Any endoscopy* 1,227 (60.2) 2,533 (67.8) <0.001 545 (61.1) 432 (61.0) 250 (57.1) 0.32 
     Esophago-/gastro-/duodenoscopy 973 (47.7) 2,120 (56.8) <0.001 405 (45.4) 358 (50.6) 210 (48.0) 0.12 
     Colonoscopy/sigmoidoscopy 472 (23.2) 810 (21.7) 0.19 259 (29.0) 145 (20.5) 68 (15.3) <0.001 
     Proctoscopy/anoscopy 23 (1.1) 22 (0.6) 0.03 14 (1.6) 5 (0.7) 4 (0.9) 0.24 
     Enteroscopy 6 (0.3) 18 (0.5) 0.29 1 (0.1) 5 (0.7) 0 (0.0) 0.07 
     Capsule 12 (0.6) 16 (0.4) 0.40 5 (0.6) 6 (0.9) 1 (0.2) 0.45 
*Some patients have undergone different endoscopic procedures. Thus, these patients count in more than one category of endoscopic procedures. 
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eTable 1. ICD-8 and -10 codes 
Comorbidity ICD-8 and ICD-10 codes 
Gastrointestinal bleeding ICD-10: 
Upper: K250, K252, K254, K256, K260, K262, 
K264, K266, K270, K272, K274, K276, K280, 
K282, K284, K286, K290, K298A, K920, K921 
Lower: K625 
Unspecified: K922, K638B, K638C 
  
Ischemic heart disease ICD-10: I20-I25 
ICD-8: 410-414 
 
Heart failure ICD-10: I42, I50, J81, I110, I130, I132 
ICD-8: 425, 428, 4270, 4271 
 
Atrial fibrillation ICD-10: I48 
ICD-8: 4274 
 
Ischemic stroke ICD-10: I63, I64 
ICD-8: 433, 434 
 
Transient cerebral ischemia ICD-10: G45 
ICD-8: 435 
 
Thrombosis or embolism in peripheral arteries ICD-10: I74 
ICD-8: 444 
 
Peripheral vascular disease ICD-10: I70 
ICD-8: 440 
 
Coagulopathy ICD-10: D66-D69 
ICD-8: 286 
 
Deep vein thrombosis ICD-10: I801-I803, I808, I809, I821-I823, I828, I829 
ICD-8: 45100, 45108, 45109, 45190, 45199, 45300, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
  26 
45302, 45303, 45304, 45309 
 
Pulmonary embolism ICD-10: I26 
ICD-8: 450 
 
Malignancy ICD-10: C00-C97 (if not C44) 
ICD-8: 140-209 (if not 173) 
 
Chronic renal disease ICD-10: E102, E112, E132, E142, I120, N02-N08, 
N11, N12, N14, N18, N19, N26, N158-N160, N162-
N164, N168, M300, M313, M319, M321B, Q612, 
Q613, Q615, Q619, T858, T859, Z992 
ICD-8: 403, 404, 581-584, 25002, 40039, 59009, 
59320, 75310, 75311, 75319 
 
Chronic obstructive pulmonary disease ICD-10: J42-J44 
ICD-8: 490-492 
 
 Liver disease ICD-10: B15-B19, K70-K77, C22, I982, Z944, 
D684C, Q618A 
ICD-8: 070, 155, 571-573 
 
Alcohol abuse ICD-10: E244, E52, F10, G312, G621, G721, I426, 
K292, K70, K860, L27A, O354, T51, Z714, Z721 
ICD-8: 291, 303, 57109, 57110, 57710 
 
ICD, International Classification of Diseases  
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eTable 2. ATC classification codes 
Pharmacotherapy ATC codes 
Beta-blockers 
 
C07, C09BX 
Calcium channel blockers 
 
C08, C07F, C09BB, C09DB 
Renin-angiotensin-system inhibitors 
 
C09 
Vasodilator drugs 
 
C02DB, C02DD, C02DG 
Antiadrenergic drugs 
 
C02A, C02B, C02C 
Thiazides 
 
C03A, C07B, C07D, C09XA52, C03EA01 
Loop diuretics 
 
C03C, C03EB01, C03EB02 
Spironolactone 
 
C03DA01 
Anti-diabetics 
 
A10 
Aspirin 
 
B01AC06, N02BA01 
ADP-receptor inhibitors 
 
B01AC04, B01AC22, B01AC24 
Dipyridamole 
 
B01AC07 
Vitamin K antagonists 
 
B01AA03, B01AA04 
Non-vitamin K antagonists 
 
B01AE07, B01AF01, B01AF02 
Drugs used in alcohol dependence 
 
N07BB 
Non-steroidal anti-inflammatory drugs 
 
M01A 
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ATC, Anatomical Therapeutic Chemical; ADP, adenosine diphosphate  
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eTable 3. NCSP codes 
Endoscopic procedure NCSP codes 
Esophago-/gastro-/duodenoscopy 
 
KUJC, KUJD, KJCA05, KJCA22, KJCA32, KJCA35, 
KJCA42, KJDA05, KJDA22, KJDA32, KJDA35, KJDA38, 
KJDA42, KJDH05, KJDH15, KJDH18, KJDH22, KJDH25 
 
Colonoscopy/sigmoidoscopy 
 
KUJF3, KUJF4, KJFA15, KJFA42, KJFA45, KJFA48, 
KJFA52, KJGA05, KJGA22, KJGA28, KJGA32, KJGA35 
 
Proctoscopy/anoscopy 
KUJG, KUJH 
 
Enteroscopy 
KUJF0, KUJF1, KUJF2, KUJF8 
 
Capsule 
KUJF9 
 
NCSP, NOMESCO Classification of Surgical Procedures 
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